Clinical trial
In-Patient Study In Schizophrenic Patients
NCT00197093 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00197093 |
|---|---|
| Title | In-Patient Study In Schizophrenic Patients |
| Official title | A Placebo Controlled, Double-Blind, Randomised Study Investigating the Safety, Tolerability and Pharmacokinetics of Ascending Multiple Oral Doses of SB-773812 in Male and Female Schizophrenic Patients for up to 28 Days |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | SB773812 |
| Enrollment | 60 |
| Start date | Sep 1, 2004 |
| First posted | Sep 20, 2005 |
| Last update posted | May 18, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: